Gomez-Martin, Carlos <br/><br/>
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Dec 2013 
 - 4445-52 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2013.48.9070  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Agents--therapeutic use<br/>Centromere--genetics<br/>Chromosomes, Human, Pair 17--genetics<br/>Female<br/>Gene Amplification<br/>Gene Dosage<br/>Humans<br/>Immunohistochemistry<br/>In Situ Hybridization<br/>In Situ Hybridization, Fluorescence<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Prognosis<br/>Receptor, ErbB-2--genetics<br/>Stomach Neoplasms--drug therapy<br/>Survival Analysis<br/>Trastuzumab<br/>Treatment Outcome